SLU-PP-332 100 mg capsules contain a labeled 100 mg of SLU-PP-332 per capsule. The difference from a lower-strength capsule is the amount of material per unit. For example, 100 mg is 200 times the mass of 500 mcg and 20 times the mass of 5 mg. Those ratios describe quantity, not potency, absorption or an established human dose.
What is the high-strength SLU-PP-332 difference?
βHigh dose SLU-PP-332β is a common way to describe a larger label amount. The more precise specification for this product is 100 mg per capsule. Milligrams (mg) and micrograms (mcg or Β΅g) are units of mass: 1 mg equals 1,000 mcg, and 100 mg equals 100,000 mcg.
| Reference label amount | In milligrams | 100 mg contains |
|---|---|---|
| 250 mcg | 0.25 mg | 400Γ the labeled mass |
| 500 mcg | 0.5 mg | 200Γ the labeled mass |
| 1 mg | 1 mg | 100Γ the labeled mass |
| 5 mg | 5 mg | 20Γ the labeled mass |
| 10 mg | 10 mg | 10Γ the labeled mass |
These are unit-conversion examples, not a survey of competing products or a recommendation to substitute quantities. The denominator matters: 100 mg per capsule cannot be compared with 100 mg per bottle as though they were the same specification.
The higher-content format changes how much material is contained in each labeled unit. It does not, by itself, establish improved bioavailability, stronger receptor activation, greater safety or superior results. Assay compatibility and sample preparation depend on the documented formulation and the research method.
Compare capsules, liquids and blends on the right basis
Record the compound identity, form, strength per unit and package count before comparing prices. A capsule is labeled in mg per capsule; a liquid may be labeled in mg/mL plus total volume. A combination product must identify each ingredient separately.
Total labeled compound in a capsule package = mg per capsule Γ verified capsule count. Price per labeled mg is the package price divided by that total. Do not divide a bottle price by 100 mg unless 100 mg is actually the entire bottle’s content. Keep shipping, coupons and bulk-pricing conditions separate and compare like formats.
The SLU-PP-332 100 mg product page carries current pricing, availability and volume-pricing options. Related formats have separate specification records: liquid SLU-PP-332, transdermal SLU-PP-332 and the SLU-PP-332/BAM15 blend. Their names do not establish comparable delivery or exposure.
What published SLU-PP-332 research establishes
Billon and colleagues identified SLU-PP-332 as an agonist of all three ERR subtypes, with greatest potency at ERRΞ± in their assays. The 2023 paper reported cellular respiration findings and exercise-related responses in mice. This is the research context behind the term βexercise mimeticβ; it is not evidence that a commercial capsule replaces exercise in people.[1]
A subsequent study examined metabolic outcomes in mouse models of obesity and metabolic syndrome. The authors reported changes in energy expenditure and fatty-acid oxidation in those models. Their experimental preparations and administration methods cannot establish the performance of an orally consumed 100 mg commercial capsule.[2]
SLU-PP-915 was studied alongside SLU-PP-332 in separate preclinical cardiac research. They are structurally distinct compounds. A 10 mg SLU-PP-915 label and a 100 mg SLU-PP-332 label do not establish a ten-to-one potency relationship.[3] See the SLU-PP-915 research reference.
Check identity, content and the matching COA
A label gives the product specification. A certificate reports results for the sample tested. Check the batch identifier, sample description, laboratory, date, method and units. Purity, identity and quantitative content are separate measurements; a purity percentage alone does not verify 100 mg per capsule.
Use the DA COA portal and the documentation on the capsule product page to locate the relevant record. Match it to the supplied lot, and request clarification if the format or batch differs. A certificate for liquid SLU-PP-332 or a blend is not a capsule-content result.
SLU-PP-332 100 mg questions
What does SLU-PP-332 100 mg mean?
For DA’s capsule listing, 100 mg is the labeled amount of SLU-PP-332 per capsule. It is not the total for the bottle, a liquid concentration or an established human dose.
How much larger is 100 mg than 500 mcg?
500 mcg equals 0.5 mg, so 100 mg is 200 times that labeled amount. This is a mass comparison only; it does not imply 200 times the biological effect or interchangeable formulations.
Is high-dose SLU-PP-332 more effective?
A larger label amount alone does not establish greater effectiveness. Exposure, formulation, purity, measured content and the experimental model all affect interpretation. The studies cited here do not validate the clinical performance of DA’s 100 mg capsule.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a synthetic small molecule studied as an agonist of estrogen-related receptors. Its appearance in peptide catalogs does not change its chemical class.
Can SLU-PP-332 capsules, liquids and blends be compared directly?
Compare the same compound, format and units first. Milligrams per capsule, milligrams per milliliter and milligrams per bottle describe different quantities. A blend also contains additional compounds. Equal labeled mass does not establish equal exposure.
Does a purity percentage prove capsule strength?
No. A purity result and a quantitative content result answer different questions. Match the lot, sample description, method and reported units on the relevant certificate before interpreting a content claim.
Is SLU-PP-915 10 mg equivalent to SLU-PP-332 100 mg?
No equivalence is established by those labels. SLU-PP-915 and SLU-PP-332 are distinct molecules. A tenfold difference in supplied mass is not a potency conversion.
Primary research sources
- Billon et al. (2023). Synthetic ERRΞ±/Ξ²/Ξ³ Agonist Induces an ERRΞ±-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. DOI: 10.1021/acschembio.2c00720.
- Billon et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics. DOI: 10.1124/jpet.123.001733.
- Xu et al. (2024). Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. DOI: 10.1161/CIRCULATIONAHA.123.066542.
Publisher disclosure: Disguised Alpha sells the research materials discussed here. This is a supplier-published specification and research reference. Materials are for laboratory research only, not human consumption, self-administration, veterinary, diagnostic or therapeutic use. The cited preclinical studies do not establish human safety or efficacy.